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The epidemic of Type I allergies to latex proteins appears to be
limited to healthcare workers and others who have used or been
exposed to powdered latex gloves.’ This phenomenon apparently
began with the advent of universal precautions in the late 1 980s and
the consequent ten-fold increase in the demand for latex gloves.2
Lawsuits against the manufacturers of powdered latex gloves
commenced in the 1990s. They are filed in both state courts and
federal courts. Cases tiled in Hawaii State Circuit Court have been
designated “complex litigation” and assigned to the Hon. Gail C.
Nakatani. Cases filed in federal courts have all been temporarily
transferred by the Multi-District Litigation panel to Philadelphia
and assigned to the Hon. Edmund Ludwig. One recent jury trial in
Wisconsin resulted in a verdict of $l,000,OO0. Documents pro
duced by the manufacturers have been subjected to court protective
orders which prohibit even alluding to their contents. Yet, published
articles on this topic contend that the manufacturers shortened or
eliminated the post-oven leaching time of their latex gloves and thus
produced gloves with high extractable protein content.4 Some
members of the industry appear to concede that changes in the
manufacturing process, such as the shift from alcohol coagulants to
water and decreasing the use of zinc-bearing components may be
one of the factors in the increase in Type I reactions to latex.5
Leaching has long been described in the manufacture of “rubber
gloves” as “probably reduc[ingj the risk ofdermatitis to the wearer.”6
Persons with Type I allergies have at least two parallel legal
recourses: (1) filing worker’s compensation claims for occupational
disease (which provided limited benefits) and (2) filing product
liability actions against latex glove manufacturers (which provide
full compensation for losses). Occupational diseases, including
disabling allergies, have long been compensable under state work
ers’ compensation laws.7 A causal connection between work and the
disease is sufficient. Product liability is more complex. Under
Hawaii law, a manufacturer is liable to end-users for personal injury
and disease caused by its defective products. A product is defective
if rendered dangerous by a flaw in the manufacturing process, or it
is defectively designed, or if the manufacturer fails to warn of
dangers in the expected uses of the product by the public.6 A product
is deemed defectively designed if (I) it is not as safe as an ordinary
consumer or user would expect when used in a reasonably foresee-
Correspondence to:
Gary 0. Galiher JD and
L. Richard DeRobertis JO
610 Ward Aye, #200
Honolulu, HI 9681 43308
able manner; or (ii) the benefits of the product as designed are
outweighed by the dangers imposed by the product.9
To the extent that latex glove manufacturers decreased the total
leach time to below the industry standard and this resulted in a higher
level of latex proteins in the finished product, this would establish
liability under both the manufacturing defect (i.e., flaw in the
manufacturing process) and the balancing test for defectively de
signed products. That is, a product designed to have more latex
proteins in the finished product than is otherwise necessary produces
no added benefit to the end-user compared to the protective benefits
already present in a properly leached latex glove.
A parallel theory of liability of the latex glove manufacturers is
their failure to warn. Under well-established Hawaii law, a manu
facturer is negligent if it fails to warn of the reasonably foreseeable
dangers in its products.”> It is established in the published literature
that the latex glove industry knew since the 1930’s that certain
individuals can become sensitized to the naturally occurring pro
teins in latex gloves.” Therefore, the manufacturers had both a duty
to eliminate the dangerous levels of latex proteins from the finished
product and to warn end-users of the risks inherent in high protein
powdered latex gloves. Failure to warn liability can also be
established if the warnings were inadequate or rnisieading.2Thus,
latex glove manufacturers which promoted their products as
“hypoallergenic” when in fact they had high levels of protein
allergens could be found negligent and consequently liable for
sensitizing healthcare workers who develop Type I systemic aller
gies. Numerous documents in the public domain indicate that the
latex manufacturers, through the trade association, Health Industry
Manufacturers Association, actively resisted discontinuing the claims
of “hypoallergenic” for latex gloves. On June 24, 1996, the FDA
proposed that the term “hypoallergenic” be eliminated because it is
false and misleading in that it incorrectly implies that the product
labelled as “hypoallergenic” may be used safely by latex sensitive
persons.’3
It is vital for anyone with a Type I allergy to understand that
their claims against the manufacturers and for worker’s compensa
tion benefits are subject to statutes of limitations. That is, a claim for
being exposed and sensitized to latex proteins through powdered
gloves will be barred if a legal action is not promptly filed. The exact
knowledge which triggers the running of the statute of limitations is
a technical legal issue and depends upon the particular facts of each
individual case. Indeed, the elements triggering the running of the
statute of limitations have been the subject of numerous appellate
court opinions.’4No healthcare worker should assume his/her claim
is already barred; nor should he/she assume that it is safe to delay
seeking legal advice.
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Scientists report that half of all cases of dog and
cat bites carry pasteurella which can cause septi
cemia, bursitis and even meningitis. (JAMA &
NEJM)
A recent study says calcium supplements
(I ,200mg/d) reduce the growth of colon ad
enomas. Researchers theorize that calcium binds
with compounds that irritate the colon lining.
(Time 1/25/99)
Mayo Clinic reports that 639 women with mod
erate to high risk of developing breast cancer
underwent prophylactic mastectomies form 1960
to 1993, thus reducing their risk of dying from
breast cancer by 90% (a figure which is debat
able). Researchers have identified two major
genes BRAC 1 and BRAC 2 whose mutations
increase breast and ovarian cancers. Tests for
these genetic mutations cost $2,400 for the first
test per family and $400 for subsequent tests...
(Time 1/25/99)
Medical Tid Bits Ill...
FDA has approved a hand-held imaging device
called T Scan 2000 which sends tiny jolts of
electricity into mammogram detected breast tu
mors. Malignant cells apparently conduct
electricity differently from normal cells. The
scan may prevent 200,000 unnecessary biopsies
per year.
Root Canal specialists say that when a tooth
gets knocked out, put it in a glass of milk. Milk
keeps the tooth alive by nourishing the root cells
for at least an hour.
The Wall Street Journal reports 10 deaths and
11 cases of GI hemorrhage attributed to Celebrax.
Monsanto says there is no proof that the drug
caused the deaths. Since January, 2.5 million
prescriptions have been written for the drug.
(Time 5/3/99)
Eating an egg a day won’t keep the doctor away,
but probably won’t hurt your heart either or cause
a stroke per JAMA. Researchers from Harvard
and Brigham and Woman’s Hospital in Boston
studied egg consumption by 120,000 nurses and
other healthy professionals with normal choles
terol levels and found no link between eggs and
heart disease or stroke (except in diabetics)
Dietary fat may be unhealthy for the heart, but
will not cause breast cancer according to a study
involving 90,000 women.
Viagra may not work for women according to
preliminary data. Thirty post menopausal women
took the drug and only 21% reported improved
sexual function viz enhanced desire and easily
achieved orgasms... (Time 3/22/99)
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